Category: Did You Know

Yasmeen Lari is Pakistan’s first female architect who designed famous buildings of Pakistan

Architect Yasmeen Lari is Pakistan’s first female architect. She started her career in the early 1990s, building some of Karachi’s most iconic structures. She has worked on projects such as the Taj Mahal Hotel, Finance and Trade Centre, and the Pakistan State Oil House, achieving success in a profession dominated by men.

Shazia Parveen is Pakistan’s first female firefighter

Shazia Parveen has been recognized as Pakistan’s first female firefighter. In 2010, she was only 22 when she joined the rescue service in the district of Vehari, Punjab province. She chose to take on the challenging job with a mission to serve and save the people. She also served as a fire instructor at the Punjab Emergency Services Academy in Lahore.

Fatima Changezi is first female naval officer to join Navy from Gilgit

Fatima Changezi was the first female naval officer to join the Navy from Gilgit. As a sub-lieutenant, she completed the 23rd Short Service Commission and received a gold medal. It became Fatima’s honor to become the first woman in her family to complete a psychology degree. Fatima’s decision to join the military was at the request of her father.

Did you know Angelina Jolie gave the name Princess of Hope to the statue?

The famed statue of ‘Princess of Hope’ located in the heart of Hingol national park is situated in Balochistan. Hingol National Park is famous for its rock formations and mud volcanos. It is the biggest and one of Pakistan’s most unique national parks. But did you know, the statue was given its name by Hollywood actress Angelina Jolie?

4-year-old Arish from Karachi holds title for being youngest Microsoft professional In world after Arfa Karim

Arish Fatima, a 4-year-old prodigy from Karachi, is the youngest Microsoft professional after Arfa Karim. In 2021, Arish Fatima set an example for all by scoring 831 marks in the Microsoft Certified Professional (MCP) exam. In order to pass the MCP exam, one must score 700 points, but Arish broke a world record and made Pakistan proud around the world.

Did you know? Glitter is a microplastic which is environmentally hazardous

When finding glitter in every nook and cranny was not enough, the sparkly microplastic reached the seas and oceans. Usually made from a combination of aluminum and plastic, glitter is sold in its most environmentally hazardous format from the beginning. This year, several British retailers have announced there will be no glitter in their store-brand Christmas products such as crackers, wrapping paper and gift bags.

Coronavirus may never go away, warns WHO

The World Health Organization on Wednesday warned that the novel coronavirus may never go away and become an endemic – like HIV. Also that the world must learn to live with. As the world gradually eases the stringent measures it took to stem the outbreak’s spread, the WHO says the virus may never be wiped out completely.

COVID-19 may begin with digestive symptoms in children: study

COVID-19 may begin with digestive symptoms in children as a rare inflammatory syndrome similar to Kawasaki disease was reported in some children in Europe and US. Earlier, it was believed that children are mostly asymptomatic carriers of the virus. The disease is might begin with diarrhoea and other gastrointestinal symptoms, not cough.

UAE develops a breakthrough treatment for COVID-19

Researchers at the Abu Dhabi Stem Cell Center (ADSCC) have developed an innovative treatment for COVID-19 that uses stem cells to cure the infection. This treatment involves extracting stem cells from the patient’s blood and reintroducing them to the lungs through inhalation of a fine mist. The mist has a therapeutic effect as it enables the lung cells to regenerate and change the response of the immune system. 

Antiviral drug shows promise against COVID-19 in clinical trials

The antiviral drug Remdesivir has shown promising results in the treatment of COVID-19 in clinical trials. Two trials of the drug were carried out: one by the US National Institute of Allergy and Infectious Diseases and the other by Gilead Sciences. More than 1,000 patients across the globe took part in NIAID’s trial. Treatment with Remdesivir was compared with supportive care with a placebo.